Key result
Cardiovascular G protein-coupled receptor autoantibodies do not differ between POTS patients and healthy controls.
Why the study?
The pathophysiology of POTS is not fully understood, but autoimmunity may play a role; this study aimed to compare cardiovascular G protein-coupled receptor autoantibody concentrations between patients with POTS and healthy controls.
Do concentrations of autoantibodies to cardiovascular G protein-coupled receptors differ between patients with POTS and healthy controls?
Case-Control (n=197)
Yes
Do concentrations of autoantibodies to cardiovascular G protein-coupled receptors differ between patients with POTS and healthy controls?
Absolute Event Rate: 98.3% vs 100%
Commercially available ELISA tests for cardiovascular G protein-coupled receptor autoantibodies do not differentiate between patients with POTS and healthy controls, suggesting they are not useful for establishing an autoimmune etiology in POTS.
ELISA assays lack diagnostic utility in POTS; leaves open refined testing or alternative autoimmune mechanisms.
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is a disorder of orthostatic intolerance that primarily affects women of childbearing age. The underlying pathophysiology of POTS is not fully understood, but it has been suggested that autoimmunity may play a role. The aim of this study was to compare concentrations of autoantibodies to cardiovascular G protein-coupled receptors between patients with POTS and healthy controls. METHODS: Sera were collected from 116 patients with POTS (91% female; medium age, 29 years) and 81 healthy controls (84% female; medium age, 27 years) from Calgary, Canada, and Malmö, Sweden. Samples were evaluated for autoantibodies to 11 receptors (adrenergic, muscarinic, angiotensin II, and endothelin) using a commercially available enzyme-linked immunosorbent assay. RESULTS: Autoantibody concentrations against all of the receptors tested were not significantly different between controls and patients with POTS. The majority of patients with POTS (98.3%) and all controls (100%) had α1 adrenergic receptor autoantibody concentrations above the seropositive threshold provided by the manufacturer (7 units/mL). The proportion of patients with POTS versus healthy controls who fell above the diagnostic thresholds was not different for any tested autoantibodies. Receiver operating characteristic curves showed a poor ability to discriminate between patients with POTS and controls. CONCLUSIONS: Patients with POTS and healthy controls do not differ in their enzyme-linked immunosorbent assay-derived autoantibody concentrations to cardiovascular G protein-coupled receptors. These findings suggest that these tests are not useful for establishing the role of autoimmunity in POTS.
No takes yet. Share an insight, caveat, or question.
Hall et al. (2022) conducted a case-control in Postural orthostatic tachycardia syndrome (POTS) (n=197). ELISA for autoantibodies to cardiovascular G protein-coupled receptors vs. Healthy controls was evaluated on Proportion above seropositive threshold for α1 adrenergic receptor autoantibodies. Autoantibody concentrations to cardiovascular G protein-coupled receptors measured by ELISA did not significantly differ between patients with POTS and healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: